Barclays lowered the firm’s price target on Celldex (CLDX) to $21 from $25 and keeps an Underweight rating on the shares following the Q3 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating
- Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress
- Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
- Celldex reports Q3 EPS ($1.01), consensus (89c)
- Celldex appoints Lawver as Chief Commercial Officer